NIH Guide for Grants and Contracts - November 07, 2008

Here are some of the latest Notices and Funding Opportunities from the NIH. For the entire Guide, please go to this website: http://grants.nih.gov/grants/guide/WeeklyIndex.cfm?WeekEnding=11-07-2008

If you are interested in applying to any of these extramural funding opportunities, please contact Dr. Toya Randolph, Director of Sponsored Programs ( trandolph@usuhs.mil ) or your grants management specialist.


Weekly NIH Funding Opportunities and Notices
NIH Guide for Grants and Contracts
November 07, 2008
Table of Contents (TOC)
All NIH Funding Opportunities and Notices


Notices

Findings of Scientific Misconduct
(NOT-OD-09-014)
Department of Health and Human Services
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-014.html

Notice is hereby given that the Office of Research Integrity (ORI) and the Acting Assistant Secretary for Health have taken final action in the following case: Jusan Yang, M.S., M.D. at the University of Iowa



Clarification on New NIH Policy on Resubmission (Amended) Applications
(NOT-OD-09-016)
National Institutes of Health
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-016.html
The notice states, 'Beginning with applications intended for the January 25, 2009 due date, all original new applications (i.e., never submitted) and competing renewal applications will be permitted only a single amendment (A1)'. This statement has been misunderstood by some to mean that the receipt dates have been changed. To clarify, NIH receipt dates have not been changed. The reason why January 25, 2009 is listed as the date at which the policy commences is because it is intended that the policy will take effect beginning with applications submitted for award in fiscal year 2010 and the first standard receipt date for fiscal year 2010 is January 25, 2009.



Error correction window extended to November 14, 2008 for NIH, AHRQ and NIOSH grant applications due November 3-10, 2008
(NOT-OD-09-017)
National Institutes of Health
Agency for Healthcare Research and Quality
National Institute for Occupational Safety and Health


Requests for Applications

Brain Imaging Studies of Negative Reinforcement in Humans (R01)
(RFA-DA-09-008)
National Institute on Drug Abuse
Application Receipt Date(s): February 19, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-008.html
This FOA issued by National Institute on Drug Abuse, National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/ organizations that propose to investigate brain processes in humans underlying how aversive events control behavior in order to stimulate a program of clinical neuroscience research on negative reinforcement / avoidance learning. On the basis of pre-clinical studies, negative reinforcement has re-emerged as a contributing factor in the basic processes of substance abuse. The range of processes engaged by the human brain to avoid aversive outcomes are much less well understood than that of brain processes engaged by positive outcomes. For the purpose of this FOA negative reinforcement and avoidance learning are considered synonymous and refer to behaviors and cognitive strategies that are learned and maintained in order to minimize or eliminate the occurrence of aversive events. Aversive events may be either environmental stimuli or internal states. Applications for this FOA are expected to propose hypotheses-testing studies regarding the brain regions or processes in humans that underlie avoidance learning including behaviors and cognitive strategies maintained by negative reinforcement. The studies proposed in response to this FOA may be conducted in healthy individuals, substance-abusing populations (current or abstinent) or individuals at risk for substance abuse. However, all applications must address how the proposed investigations are relevant to advancing the understanding of substance abuse.



Brain Imaging Studies of Negative Reinforcement in Humans (R21)
(RFA-DA-09-009)
National Institute on Drug Abuse
Application Receipt Date(s): February 19, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-009.html

This FOA issued by National Institute on Drug Abuse, National Institutes of Health, solicits Exploratory/Developmental Grant (R21) applications from institutions/ organizations that propose to investigate brain processes in humans underlying how aversive events control behavior in order to stimulate a program of clinical neuroscience research on negative reinforcement / avoidance learning. On the basis of pre-clinical studies, negative reinforcement has re-emerged as a contributing factor in the basic processes of substance abuse. The range of processes engaged by the human brain to avoid aversive outcomes are much less well understood than that of brain processes engaged by positive outcomes. For the purpose of this FOA negative reinforcement and avoidance learning are considered synonymous and refer to behaviors and cognitive strategies that are learned and maintained in order to minimize or eliminate the occurrence of aversive events. Aversive events may be either environmental stimuli or internal states. Applications for this FOA are expected to propose exploratory, hypotheses-generating or proof of concept studies regarding the brain regions or processes in humans that underlie avoidance learning including behaviors and cognitive strategies maintained by negative reinforcement. This FOA is also appropriate for the development of new tasks in humans that may be used in future brain imaging studies to target specific brain processing areas affected by negative reinforcement/avoidance learning. The studies proposed in response to this FOA may be conducted in healthy individuals, substance-abusing populations (current or abstinent) or individuals at risk for substance abuse. However, all applications must address how the proposed investigations are relevant to advancing the understanding of substance abuse.



Secondary Data Analyses for Substance Abuse Research (R21/R33)
(RFA-DA-09-020)
National Institute on Drug Abuse
Application Receipt Date(s): January 28, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-020.html

This funding opportunity, issued by the National Institute on Drug Abuse invites Phased Innovation (R21/R33) grant applications from organizations/institutions that propose to conduct secondary analyses of rich biological data sets related to substance abuse research and to advance data and computational infrastructure relevant to the proposed analyses.



1000 Genomes Project Data Processing (U01)
(RFA-HG-09-001)
National Human Genome Research Institute
Application Receipt Date(s): January 12, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-09-001.html

The international 1000 Genomes Project is designed to produce a new high-resolution resource on human genetic variation to support genome-wide association studies and other studies of human disease and biology. This FOA solicits proposals to continue to develop, evaluate, and implement the methods needed to monitor data quality, to produce a basic set of derived data types from the sequence data, to integrate those data, and to develop new tools for additional data analysis to produce the final Project dataset. Projects funded under this FOA will be expected to participate in the highly collaborative international consortium that is carrying out the 1000 Genomes Project.



1000 Genomes Project Dataset Analysis (U01)v
(RFA-HG-09-002)
National Human Genome Research Institute
Application Receipt Date(s): June 26, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-09-002.html

The international 1000 Genomes Project is designed to produce a new high-resolution resource on human genetic variation to support genome-wide association studies and other studies of human disease and biology. The primary source of data will be light sequencing of the genomes of about 1200-1500 anonymized individuals. These data should be sufficient to find most DNA sequence variants in the human population that have a frequency of 1% or more. Several large-scale sequencing centers, including three funded by NHGRI, are involved in this international effort. Currently pilot projects are underway to assess the sequencing platforms and provide data that will be used to design the full-scale project. By the end of 2008 the full-scale project should be underway; it is expected to take about two years and produce about 20 Terabases of sequence data. The Project regularly will release raw sequence data and data derived from the sequence data, such as genotype calls for single-nucleotide polymorphisms (SNPs) and structural variants, and their linkage disequilibrium patterns. This FOA solicits proposals to characterize and analyze the full dataset, such as for allele frequency distribution and signals of natural selection, to produce additional data types, to evaluate the strategies used to develop the dataset, and to develop the tools needed to work with the data and apply them to other studies such as genome-wide association studies.



Instrument Development for Biomedical Applications (R21)
(RFA-RR-09-001)
National Center for Research Resources
Application Receipt Date(s): January 27, 2009, September 30, 2009
http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-09-001.html

This funding opportunity announcement (FOA), issued by the National Center for Research Resources (NCRR), solicits innovative applications for the development of new or improved instrumentation for biomedical research. Projects should propose tools that can be used by a wide range of biomedical or clinical researchers, and not limited to a specific organ or disease.

Program Announcements

Erythropoiesis Stimulating Agents and Tumor Progression (R01)
(PA-09-023)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
http://grants.nih.gov/grants/guide/pa-files/PA-09-023.html

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression.


Erythropoiesis Stimulating Agents and Tumor Progression (R21)
(PA-09-024)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
http://grants.nih.gov/grants/guide/pa-files/PA-09-024.html

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression.

Resources